Firm behind Singapore's potential vaccine to test freeze-dried version

Arcturus Therapeutics is looking at a freeze-dried version of its mRNA vaccine that could work well at room temperature.
Arcturus Therapeutics is looking at a freeze-dried version of its mRNA vaccine that could work well at room temperature.PHOTO: REUTERS

Singapore's potential Covid-19 vaccine could well be one which can be manufactured, shipped and stored with ease, as the company behind it is working on a version which does not need ultra-cold conditions for it to survive.

Arcturus Therapeutics, a US-based biotechnology company developing a Covid-19 vaccine with the Duke-NUS Medical School here, is looking at a lyophilised or freeze-dried version of its mRNA vaccine that could work well at room temperature, unlike other similar vaccines.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*

*Terms and conditions apply.

A version of this article appeared in the print edition of The Straits Times on October 08, 2020, with the headline 'Firm behind S'pore's potential vaccine to test freeze-dried version'. Print Edition | Subscribe